In this study, the pharmacokinetics of moxifloxacin (5 mg/kg) was determined following a single intravenous administration of moxifloxacin alone and co-administration with diclofenac (2.5 mg/kg) or flunixin meglumine (2.2 mg/kg) in sheep. Six healthy Akkaraman sheep (2 ± 0.3 years and 53.5 ± 5 kg of body weight) were used. A longitudinal design with a 15-day washout period was used in three periods. In the first period, moxifloxacin was administered by an intravenous (IV) injection. In the second and third periods, moxifloxacin was co-administered with IV administration of diclofenac and flunixin meglumine, respectively. The plasma concentration of moxifloxacin was assayed by high-performance liquid chromatography. The pharmacokinetic parameters were calculated using a two-compartment open pharmacokinetic model. Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively. While diclofenac and flunixin meglumine significantly increased the t1/2β and AUC of moxifloxacin, they significantly reduced the ClT and Vdss . These results suggest that anti-inflammatory drugs could increase the therapeutic efficacy of moxifloxacin by altering its pharmacokinetics.

中文翻译：

---

在绵羊中与氟尼辛葡甲胺或双氯芬酸同时给药后，莫西沙星的静脉药代动力学。

在这项研究中，在单独静脉注射莫西沙星并与双氯芬酸（2.5 mg / kg）或氟尼辛葡甲胺（2.2 mg / kg）共同在绵羊中单次静脉内给药后，确定了莫西沙星（5 mg / kg）的药代动力学。使用六只健康的阿克卡拉曼羊（2±0.3岁，体重53.5±5 kg）。在三个阶段中使用了具有15天淘汰期的纵向设计。在第一阶段，莫西沙星通过静脉注射给药。在第二和第三阶段，莫西沙星分别与双氯芬酸和氟尼辛葡甲胺静脉注射共同给药。用高效液相色谱法测定莫西沙星的血浆浓度。使用两室开放式药代动力学模型计算药代动力学参数。单独静脉注射莫西沙星后，平均消除半衰期（t1 /2β），总体清除率（ClT），稳态时的分布体积（Vdss）和莫西沙星的曲线下面积（AUC）为2.27 hr，0.56 L h-1 kg-1，1.66 L / kg和8.91 hr * µg / ml。尽管双氯芬酸和氟尼辛葡甲胺显着增加了莫西沙星的t1 /2β和AUC，但它们却显着降低了ClT和Vdss。这些结果表明抗炎药可以通过改变其药代动力学来提高莫西沙星的治疗效果。尽管双氯芬酸和氟尼辛葡甲胺显着增加了莫西沙星的t1 /2β和AUC，但它们却显着降低了ClT和Vdss。这些结果表明，抗炎药可以通过改变莫西沙星的药代动力学来提高其疗效。尽管双氯芬酸和氟尼辛葡甲胺显着增加了莫西沙星的t1 /2β和AUC，但它们却显着降低了ClT和Vdss。这些结果表明，抗炎药可以通过改变莫西沙星的药代动力学来提高其疗效。